29 clinical trials matched your search for Pancreatic Cancer. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Pancreatic Cancer The Cancer of the Pancreas Screening-5 Study (CAPS5 Study) Fay Kastrinos, MD
Pancreatic Cancer Study of Stimulation with Bethanechol in Pancreatic Adenocarcinoma Prior to Surgery Susan Bates, MD
Pancreatic Cancer Chemo4METPANC: Combination of Chemotherapy, Motixafortide, and Cemiplimab in Patients with Pancreatic Cancer Gulam Manji, MD, PhD
Pancreatic Cancer Study of Bethanechol in Combination with Chemotherapy for Patients with Pancreatic Cancer Susan Bates, MD
Pancreatic Cancer Study of SBP-101 Alone or in Combination with Chemotherapy in Patients with Untreated Pancreatic Ductal Adenocarcinoma (PDAC) Gulam Manji, MD, PhD
Pancreatic Cancer Study of Zimberelimab in Patients with Advanced Pancreatic Cancer who are Eligible for Surgery Gulam Manji, MD, PhD
Pancreatic Cancer Study of Autogene Cevumeran & Atezolizumab Alone or in Combination with mFOLFIRINOX in Patients with Resected Pancreatic Cancer (PDAC) Gulam Manji, MD, PhD
Pancreatic Cancer Study of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Pancreatic Cancer Gulam Manji, MD, PhD
Pancreatic Cancer Study of ASP2138 in Patients with Stomach or Pancreatic Cancer Ryan Moy, MD
Cancer Study of IDE196 in Patients with Solid Tumors Alexander Wei, MD
Cancer Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) Brian Henick, MD
Cancer Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Catherine Shu, MD
Cancer Study of Investigational Drug (RP-6306) in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of Financial Navigator Addressing Cancer-Related Financial Hardship in Cancer Patients and Their Spouses Dawn Hershman, MD
Cancer Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer Benjamin Herzberg, MD
Cancer Study of IDE397 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of CS5001 in Patients with Advanced Solid Tumors Hua-Jay Cherng, MD
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation Benjamin Herzberg, MD
Cancer Study of 68Ga-FAP-2286 and 177Lu-FAP-2286 in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer Brian Henick, MD
Cancer Study of LNS8801 Alone or in Combination with Pembrolizumab in Patients with Advanced Cancer Brian Henick, MD
Cancer Study of RMC-6291 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of MRT-2359 in Patients with Solid Tumors Benjamin Herzberg, MD
Cancer Study of RMC-6236 in Patients with Solid Tumors with a KRAS Mutation Benjamin Herzberg, MD
Cancer Study of NDI-101150 Alone or in Combination with Pembrolizumab in Patients with Solid Tumors Ryan Moy, MD
Cancer Study of XmAb808 in Combination with Pembrolizumab in Patients with Advanced Cancer Mark Stein, MD
Cancer Study of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors Ryan Moy, MD
Cancer Study of HRO761 Alone or in Combination with Tislelizumab or Irinotecan in Patients with Solid Tumors Edmond Chan, MD
Gastrointestinal Study of ASP2138 in Patients with Stomach or Pancreatic Cancer Ryan Moy, MD
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE